Epigenetic down-regulation of integrin α7 increases migratory potential and confers poor prognosis in malignant pleural mesothelioma

Journal of Pathology

Volumn 237, Issue 2, 2015, Pages 203-214

  Laszlo, Viktoria ^a,b   Hoda, Mir Alireza ^a   Garay, Tamas ^b,c   Pirker, Christine ^d   Ghanim, Bahil ^a   Klikovits, Thomas ^a   Dong, Yawen W ^a   Rozsas, Anita ^a,e   Kenessey, Istvan ^c   Szirtes, Ildiko ^c   Grusch, Michael ^d   Jakopovic, Marko ^f   Samarzija, Miroslav ^f   Brcic, Luka ^g,h   Kern, Izidor ⁱ   Rozman, Ales ⁱ   Popper, Helmut ^h   Zöchbauer Müller, Sabine ^a   Heller, Gerwin ^a   Altenberger, Corinna ^a   Ziegler, Barbara ^a   Klepetko, Walter ^a   Berger, Walter ^d   Dome, Balazs ^a,c,e   Hegedus, Balazs ^a,d,j   more..

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

^b EÖTVÖS LORÁND UNIVERSITY   (Hungary)

^c SEMMELWEIS UNIVERSITY   (Hungary)

^d MEDICAL UNIVERSITY OF VIENNA   (Austria)

^e NATIONAL KORANYI INSTITUTE OF PULMONOLOGY   (Hungary)

^f KBC Zagreb   (Croatia)

^g UNIVERSITY OF ZAGREB   (Croatia)

^h MEDICAL UNIVERSITY OF GRAZ   (Austria)

ⁱ UNIVERSITY CLINIC OF RESPIRATORY AND ALLERGIC DISEASES   (Slovenia)

^j INSTITUTE OF EXPERIMENTAL MEDICINE   (Hungary)

more..

Author keywords

cell migration; integrin; malignant pleural mesothelioma; prognosis; promoter methylation; tumour suppressor gene

Indexed keywords

ALPHA7 INTEGRIN; MESSENGER RNA; ALPHA INTEGRIN; LAMININ; LEUKOCYTE ANTIGEN; TUMOR SUPPRESSOR PROTEIN;

ARTICLE; CANCER PROGNOSIS; CELL CULTURE; CELL MIGRATION; CELL MOTILITY; CONTROLLED STUDY; DNA METHYLATION; DOWN REGULATION; EPIGENETICS; GENE EXPRESSION; GENETIC TRANSCRIPTION; HISTOPATHOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VITRO STUDY; MAJOR CLINICAL STUDY; MESOTHELIOMA CELL LINE; MESOTHELIUM CELL; MICROARRAY ANALYSIS; OVERALL SURVIVAL; PLEURA MESOTHELIOMA; PRIORITY JOURNAL; PROMOTER REGION; TUMOR GENE; TUMOR SUPPRESSOR GENE; CELL MOTION; DNA MICROARRAY; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; GENETIC EPIGENESIS; GENETIC TRANSFECTION; GENETICS; GENOME-WIDE ASSOCIATION STUDY; KAPLAN MEIER METHOD; LUNG TUMOR; MESOTHELIOMA; METABOLISM; MORTALITY; MULTIVARIATE ANALYSIS; PATHOLOGY; PLEURA TUMOR; PROCEDURES; PROGNOSIS; PROPORTIONAL HAZARDS MODEL; RISK FACTOR; SIGNAL TRANSDUCTION; TIME FACTOR; TUMOR CELL LINE; TUMOR INVASION;

ANTIGENS, CD; CELL LINE, TUMOR; CELL MOVEMENT; DNA METHYLATION; DOWN-REGULATION; EPIGENESIS, GENETIC; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; GENOME-WIDE ASSOCIATION STUDY; HUMANS; INTEGRIN ALPHA CHAINS; KAPLAN-MEIER ESTIMATE; LAMININ; LUNG NEOPLASMS; MESOTHELIOMA; MULTIVARIATE ANALYSIS; NEOPLASM INVASIVENESS; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; PLEURAL NEOPLASMS; PROGNOSIS; PROMOTER REGIONS, GENETIC; PROPORTIONAL HAZARDS MODELS; RISK FACTORS; RNA, MESSENGER; SIGNAL TRANSDUCTION; TIME FACTORS; TRANSFECTION; TUMOR SUPPRESSOR PROTEINS;

EID: 84940882661     PISSN: 00223417     EISSN: 10969896     Source Type: Journal    
DOI: 10.1002/path.4567     Document Type: Article

References (55)

1. Lin RT, Takahashi K, Karjalainen A, et al., Ecological association between asbestos-related diseases and historical asbestos consumption: an international analysis. Lancet 2007; 369: 844-849.
2. Britton M., The epidemiology of mesothelioma. Semin Oncol 2002; 29: 18-25.
3. de Perrot M, Feld R, Cho BC, et al., Trimodality therapy with induction chemotherapy followed by extrapleural pneumonectomy and adjuvant high-dose hemithoracic radiation for malignant pleural mesothelioma. J Clin Oncol 2009; 27: 1413-1418.
4. Van Schil PE, Baas P, Gaafar R, et al., Trimodality therapy for malignant pleural mesothelioma: results from an EORTC phase II multicentre trial. Eur Respir J 2010; 36: 1362-1369.
5. de Reyniès A, Jaurand MC, Renier A, et al., Molecular classification of malignant pleural mesothelioma: identification of a poor prognosis subgroup linked to the epithelial-to-mesenchymal transition. Clin Cancer Res 2014; 20: 1323-1334.
6. Iwanami T, Uramoto H, Nakagawa M, et al., Clinical significance of epithelial-mesenchymal transition-associated markers in malignant pleural mesothelioma. Oncology 2014; 86: 109-116.
7. Zhong J, Gencay MM, Bubendorf L, et al., ERK1/2 and p38 MAP kinase control MMP-2, MT1-MMP, and TIMP action and affect cell migration: a comparison between mesothelioma and mesothelial cells. J Cell Physiol 2006; 207: 540-552.
8. Song WK, Wang W, Foster RF, et al., H36-alpha 7 is a novel integrin alpha chain that is developmentally regulated during skeletal myogenesis. J Cell Biol 1992; 117: 643-657.
9. Ziober BL, Chen YQ, Ramos DM, et al., Expression of the alpha7beta1 laminin receptor suppresses melanoma growth and metastatic potential. Cell Growth Differ 1999; 10: 479-490.
10. Ren B, Yu YP, Tseng GC, et al., Analysis of integrin alpha7 mutations in prostate cancer, liver cancer, glioblastoma multiforme, and leiomyosarcoma. J Natl Cancer Inst 2007; 99: 868-880.
11. Zhu ZH, Yu YP, Zheng ZL, et al., Integrin alpha 7 interacts with high temperature requirement A2 (HtrA2) to induce prostate cancer cell death. Am J Pathol 2010; 177: 1176-1186.
12. Hoda MA, Munzker J, Ghanim B, et al., Suppression of activin A signals inhibits growth of malignant pleural mesothelioma cells. Br J Cancer 2012; 107: 1978-1986.
13. Garay T, Juhasz E, Molnar E, et al., Cell migration or cytokinesis and proliferation?-Revisiting the 'go or grow' hypothesis in cancer cells in vitro. Exp Cell Res 2013; 319: 3094-3103.
14. Livak KJ, Schmittgen TD,. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods 2001; 25: 402-408.
15. Mathieu V, Pirker C, Schmidt WM, et al., Aggressiveness of human melanoma xenograft models is promoted by aneuploidy-driven gene expression deregulation. Oncotarget 2012; 3: 399-413.
16. Ghanim B, Klikovits T, Hoda MA, et al., Ki67 index is an independent prognostic factor in epithelioid but not in non-epithelioid malignant pleural mesothelioma: a multicenter study. Br J Cancer 2015; 112: 783-792.
17. Grusch M, Schelch K, Riedler R, et al., Spatio-temporally precise activation of engineered receptor tyrosine kinases by light. EMBO J 2014; 33: 1713-1726.
18. Heller G, Schmidt WM, Ziegler B, et al., Genome-wide transcriptional response to 5-aza-2'-deoxycytidine and trichostatin A in multiple myeloma cells. Cancer Res 2008; 68: 44-54.
19. Heller G, Babinsky VN, Ziegler B, et al., Genome-wide CpG island methylation analyses in non-small cell lung cancer patients. Carcinogenesis 2013; 34: 513-521.
20. Heller G, Weinzierl M, Noll C, et al., Genome-wide microRNA expression profiling identifies miR-9-3 and miR-193a as targets for DNA methylation in non-small cell lung cancers. Clin Cancer Res 2012; 18: 1619-1629.
21. Simpson KJ, Selfors LM, Bui J, et al., Identification of genes that regulate epithelial cell migration using an siRNA screening approach. Nature Cell Biol 2008; 10: 1027-1038.
22. Pestell RG,. New roles of cyclin D1. Am J Pathol 2013; 183: 3-9.
23. Robinson BW, Musk AW, Lake RA,. Malignant mesothelioma. Lancet 2005; 366: 397-408.
24. Yao CC, Ziober BL, Squillace RM, et al., Alpha7 integrin mediates cell adhesion and migration on specific laminin isoforms. J Biol Chem 1996; 271: 25598-25603.
25. Crawley S, Farrell EM, Wang W, et al., The alpha7beta1 integrin mediates adhesion and migration of skeletal myoblasts on laminin. Exp Cell Res 1997; 235: 274-286.
26. Sigstad E, Dong HP, Nielsen S, et al., Quantitative analysis of integrin expression in effusions using flow cytometric immunophenotyping. Diagn Cytopathol 2005; 33: 325-331.
27. Klominek J, Sumitran Karuppan S, Hauzenberger D,. Differential motile response of human malignant mesothelioma cells to fibronectin, laminin and collagen type IV: the role of beta1 integrins. Int J Cancer 1997; 72: 1034-1044.
28. Reich R, Vintman L, Nielsen S, et al., Differential expression of the 67 kilodalton laminin receptor in epithelioid malignant mesothelioma and carcinomas that spread to serosal cavities. Diagn Cytopathol 2005; 33: 332-337.
29. Musti M, Kettunen E, Dragonieri S, et al., Cytogenetic and molecular genetic changes in malignant mesothelioma. Cancer Genet Cytogenet 2006; 170: 9-15.
30. Bianchi AB, Mitsunaga SI, Cheng JQ, et al. High frequency of inactivating mutations in the neurofibromatosis type 2 gene (NF2) in primary malignant mesotheliomas. Proc Natl Acad Sci U S A 1995; 92: 10854-10858.
31. Sekido Y, Pass HI, Bader S, et al., Neurofibromatosis type 2 (NF2) gene is somatically mutated in mesothelioma but not in lung cancer. Cancer Res 1995; 55: 1227-1231.
32. Lopez-Lago MA, Okada T, Murillo MM, et al., Loss of the tumor suppressor gene NF2, encoding merlin, constitutively activates integrin-dependent mTORC1 signaling. Mol Cell Biol 2009; 29: 4235-4249.
33. Bott M, Brevet M, Taylor BS, et al., The nuclear deubiquitinase BAP1 is commonly inactivated by somatic mutations and 3p21.1 losses in malignant pleural mesothelioma. Nature Genet 2011; 43: 668-672.
34. Yoshikawa Y, Sato A, Tsujimura T, et al., Frequent inactivation of the BAP1 gene in epithelioid-type malignant mesothelioma. Cancer Sci 2012; 103: 868-874.
35. Gylfe AE, Kondelin J, Turunen M, et al., Identification of candidate oncogenes in human colorectal cancers with microsatellite instability. Gastroenterology 2013; 145: 540-543.e22.
36. Giuffrida A, Vianale G, Di Muzio M, et al., Modulation of integrin expression on mesotheliomas: the role of different histotypes in invasiveness. Int J Oncol 1999; 15: 437-442.
37. Melaiu O, Cristaudo A, Melissari E, et al., A review of transcriptome studies combined with data mining reveals novel potential markers of malignant pleural mesothelioma. Mutat Res 2012; 750: 132-140.
38. Ali G, Borrelli N, Riccardo G, et al., Differential expression of extracellular matrix constituents and cell adhesion molecules between malignant pleural mesothelioma and mesothelial hyperplasia. J Thorac Oncol 2013; 8: 1389-1395.
39. Chiba T, Yokosuka O, Fukai K, et al., Cell growth inhibition and gene expression induced by the histone deacetylase inhibitor, trichostatin A, on human hepatoma cells. Oncology 2004; 66: 481-491.
40. Goto Y, Shinjo K, Kondo Y, et al., Epigenetic profiles distinguish malignant pleural mesothelioma from lung adenocarcinoma. Cancer Res 2009; 69: 9073-9082.
41. Christensen BC, Houseman EA, Godleski JJ, et al., Epigenetic profiles distinguish pleural mesothelioma from normal pleura and predict lung asbestos burden and clinical outcome. Cancer Res 2009; 69: 227-234.
42. Marsit CJ, Houseman EA, Christensen BC, et al., Examination of a CpG island methylator phenotype and implications of methylation profiles in solid tumors. Cancer Res 2006; 66: 10621-10629.
43. Tan LZ, Song Y, Nelson J, et al., Integrin alpha7 binds tissue inhibitor of metalloproteinase 3 to suppress growth of prostate cancer cells. Am J Pathol 2013; 183: 831-840.
44. Hynes RO,. Integrins: bidirectional, allosteric signaling machines. Cell 2002; 110: 673-687.
45. Kapp TG, Rechenmacher F, Sobahi TR, et al., Integrin modulators: a patent review. Expert Opin Ther Pat 2013; 23: 1273-1295.
46. Cheng NC, van Zandwijk N, Reid G,. Cilengitide inhibits attachment and invasion of malignant pleural mesothelioma cells through antagonism of integrins alphavbeta3 and alphavbeta5. PLoS One 2014; 9: e90374.
47. Buganim Y, Madar S, Rais Y, et al., Transcriptional activity of ATF3 in the stromal compartment of tumors promotes cancer progression. Carcinogenesis 2011; 32: 1749-1757.
48. Giancotti FG, Ruoslahti E,. Elevated levels of the alpha 5 beta 1 fibronectin receptor suppress the transformed phenotype of Chinese hamster ovary cells. Cell 1990; 60: 849-859.
49. Aytekin T, Ozaslan M, Cengiz B,. Deletion mapping of chromosome region 12q13-24 in colorectal cancer. Cancer Genet Cytogenet 2010; 201: 32-38.
50. Ramirez NE, Zhang Z, Madamanchi A, et al., The alpha(2)beta(1) integrin is a metastasis suppressor in mouse models and human cancer. J Clin Invest 2011; 121: 226-237.
51. Moran-Jones K, Ledger A, Naylor MJ,. Beta1 integrin deletion enhances progression of prostate cancer in the TRAMP mouse model. Sci Rep 2012; 2: 526.
52. Caswell PT, Chan M, Lindsay AJ, et al., Rab-coupling protein coordinates recycling of alpha5beta1 integrin and EGFR1 to promote cell migration in 3D microenvironments. J Cell Biol 2008; 183: 143-155.
53. Reynolds AR, Hart IR, Watson AR, et al., Stimulation of tumor growth and angiogenesis by low concentrations of RGD-mimetic integrin inhibitors. Nature Med 2009; 15: 392-400.
54. Finn RS, Brims FJ, Gandhi A, et al., Postmortem findings of malignant pleural mesothelioma: a two-center study of 318 patients. Chest 2012; 142: 1267-1273.
55. Sheldrake HM, Patterson LH,. Strategies to inhibit tumor associated integrin receptors: rationale for dual and multi-antagonists. J Med Chem 2014; 57: 6301-6315.